Commercial waste treatment program annual progress report for FY 1983

This annual report describes progress during FY 1983 relating to technologies under development by the Commercial Waste Treatment Program, including: development of glass waste form and vitrification equipment for high-level wastes (HLW); waste form development and process selection for transuranic (TRU) wastes; pilot-scale operation of a radioactive liquid-fed ceramic melter (LFCM) system for verifying the reliability of the reference HLW treatment proces technology; evaluation of treatment requirements for spent fuel as a waste form; second-generation waste form development for HLW; and vitrification process control and product quality assurance technologies

LFCM vitrification technology. Quarterly progress report, January-March 1986

This report is compiled by the Nuclear Waste Treatment Progrqam and the Hanford Waste Vitrification Program at Pacific Northwest Laboratory to document progress on liquid-fed ceramic melter (LFCM) vitrification technology. Progress in the following technical subject areas during the second quarter of FY 1986 is discussed: melting process chemistry and glass development, feed preparation and transfer systems, melter systems, canister filling and handling systems, off-gas systems, and process/product modeling and control

Commercial LFCM vitrification technology. Quarterly progress report, October-December 1984

This report is the first in a series of quarterly reports compiled by the Nuclear Waste Treatment Program Office at Pacific Northwest Laboratory to document progress on commercial liquid-fed ceramic melter (LFCM) vitrification technology. Progress in the following technical subject areas during the first quarter of FY 1985 is discussed: pretreatment systems, melting process chemistry, glass development and characterization, feed preparation and transfer systems, melter systems, canister filling and handling systems, off-gas systems, process/product modeling and control, and supporting studies. 33 figs., 12 tabs

LFCM vitrification technology. Quarterly progress report, October-December 1985

This report is compiled by the Nuclear Waste Treatment Program and the Hanford Waste Vitrification Program at Pacific Northwest Laboratory to document progress on liquid-fed ceramic melter (LFCM) vitrification technology. Progress in the following technical subject areas during the first quarter of FY 1986 is discussed: melting process chemistry and glass development, feed preparation and transfer systems, melter systems, canister filling and handling systems, off-gas systems, process/product modeling and control, and supporting studies

Long-term mortality in HIV-positive Individuals virally suppressed for >3 years with incomplete CD4 recovery

Background.\u2003Some human immunodeficiency virus (HIV)-infected individuals initiating combination antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but not CD4 cell recovery. We aimed to identify (1) risk factors for failure to achieve CD4 count >200 cells/\ub5L after 3 years of sustained viral suppression and (2) the association of the achieved CD4 count with subsequent mortality. Methods.\u2003We included treated HIV-infected adults from 2 large international HIV cohorts, who had viral suppression ( 64500 HIV type 1 RNA copies/mL) for >3 years with CD4 count 64200 cells/\ub5L at start of the suppressed period. Logistic regression was used to identify risk factors for incomplete CD4 recovery ( 64200 cells/\ub5L) and Cox regression to identify associations with mortality. Results.\u2003Of 5550 eligible individuals, 835 (15%) did not reach a CD4 count >200 cells/\ub5L after 3 years of suppression. Increasing age, lower initial CD4 count, male heterosexual and injection drug use transmission, cART initiation after 1998, and longer time from initiation of cART to start of the virally suppressed period were risk factors for not achieving a CD4 count >200 cells/\ub5L. Individuals with CD4 64200 cells/\ub5L after 3 years of viral suppression had substantially increased mortality (adjusted hazard ratio, 2.60; 95% confidence interval, 1.86-3.61) compared with those who achieved CD4 count >200 cells/\ub5L. The increased mortality was seen across different patient groups and for all causes of death. Conclusions.\u2003Virally suppressed HIV-positive individuals on cART who do not achieve a CD4 count >200 cells/\ub5L have substantially increased long-term mortality